Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 1.00 |
| ▸ | GRB2 | P62993 | 1/20 | 0.66 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.55 |
| ▸ | PGK1 | P00558 | 2/20 | 0.55 |
| ▸ | PGK2 | P07205 | 2/20 | 0.55 |
| ▸ | PTPRC | P08575 | 2/20 | 0.55 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.50 |
| ▸ | PTPRB | P23467 | 1/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | PTPRA | P18433 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphonodifluoromethyl Phenylalanine SCHEMBL2517439 | 1.00 | PTPN1 (1.00) | PTPN1GRB2SLC7A5ALPIPKM | |
| Phosphonodifluoromethyl Phenylalanine SCHEMBL9545904 | 1.00 | PTPN1 (1.00) | PTPN1GRB2SLC7A5ALPIPKM | |
| SCHEMBL27715838 | 0.88 | PTPN1 (0.78) | PTPN1GRB2PTPN2PTPN6PTPN11 | |
| SCHEMBL13997109 | 0.87 | PTPN1 (0.76) | PTPN1GRB2SLC7A5ALPIPKM | |
| SCHEMBL7831965 | 0.86 | PTPN1 (0.75) | PTPN1PTPN2PTPN6PTPN11PGK1 | |
| SCHEMBL43861 | 0.82 | GRB2 (0.76) | PTPN1GRB2SLC7A5ALPIPKM | |
| SCHEMBL148122 | 0.82 | GRB2 (0.76) | PTPN1GRB2SLC7A5ALPIPKM | |
| SCHEMBL43862 | 0.82 | GRB2 (0.76) | PTPN1GRB2SLC7A5ALPIPKM | |
| Dl-Phenylalanine SCHEMBL28313877 | 0.81 | SLC7A5 (0.71) | PTPN1GRB2SLC7A5ALPIPKM | |
| SCHEMBL2423462 | 0.81 | PTPN1 (0.67) | PTPN1GRB2SLC7A5ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4204433-A1 | INTERFERENCE PEPTIDES AS INHIBITORS OF INTERACTIONS RELATED TO AMPAR ENDOCYTOSIS | Szedlacsek, Stefan Eugen (RO) | 2023-07-05 | — | — | EP | claimed |
| WO-2022043969-A1 | INTERFERENCE PEPTIDES AS INHIBITORS OF INTERACTIONS RELATED TO AMPAR ENDOCYTOSIS | SZEDLACSEK STEFAN EUGEN (RO) | 2022-03-03 | — | — | WO | claimed |
| EP-0941232-A1 | LIGANDS FOR PHOSPHATASE BINDING ASSAY | MERCK FROSST CANADA INC. (CA) | 1999-09-15 | — | — | EP | claimed |
| WO-1998020024-A1 | LIGANDS FOR PHOSPHATASE BINDING ASSAY | MERCK FROSST CANADA & CO. (CA) | 1998-05-14 | — | — | WO | claimed |
| WO-1993025561-A1 | PHOSPHONOALKYL PHENYLALANINE COMPOUNDS SUITABLY PROTECTED FOR USE IN PEPTIDE SYNTHESIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-12-23 | — | — | WO | claimed |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4717776-A2 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | Ohio State Innovation Foundation (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4706689-A2 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | Entrada Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260008816-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| EP-0941232-A1 | LIGANDS FOR PHOSPHATASE BINDING ASSAY | MERCK FROSST CANADA INC. (CA) | 1999-09-15 | — | — | EP | disclosed |
| EP-0937157-A1 | HYDROLASE BINDING ASSAY | Merck Frosst Canada & Co. (CA) | 1999-08-25 | — | — | EP | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1998020156-A1 | HYDROLASE BINDING ASSAY | MERCK FROSST CANADA & CO. (CA) | 1998-05-14 | — | — | WO | disclosed |
| WO-1998020024-A1 | LIGANDS FOR PHOSPHATASE BINDING ASSAY | MERCK FROSST CANADA & CO. (CA) | 1998-05-14 | — | — | WO | disclosed |
| EP-0821696-A1 | PEPTIDE ANTAGONISTS OF CELLULAR MITOGENESIS AND MOTOGENESIS AND THEIR THERAPEUTIC USE | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-02-04 | — | — | EP | disclosed |
| WO-1997030079-A1 | PEPTIDE ANTAGONISTS OF CELLULAR MITOGENESIS AND MOTOGENESIS AND THEIR THERAPEUTIC USE | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008816-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | SLC3A2, SPPL2B, SLC7A1 | PTPN1 4807/4885GRB2 1778/4885SLC7A5 16/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | PTPN1 4155/4885GRB2 2747/4885SLC7A5 7/4885 |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | SLC7A1, TAP1, SLC7A5 | PTPN1 3068/4885GRB2 3766/4885SLC7A5 3/4885 |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | PTPN1 1774/4885GRB2 2053/4885SLC7A5 4/4885 |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | SLC7A1, SLC38A7, SLC6A19 | PTPN1 3098/4885GRB2 1913/4885SLC7A5 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.